208 related articles for article (PubMed ID: 16464101)
1. Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions.
Hara T; Durell SR; Myers MC; Appella DH
J Am Chem Soc; 2006 Feb; 128(6):1995-2004. PubMed ID: 16464101
[TBL] [Abstract][Full Text] [Related]
2. Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.
Cummings MD; Schubert C; Parks DJ; Calvo RR; LaFrance LV; Lattanze J; Milkiewicz KL; Lu T
Chem Biol Drug Des; 2006 Mar; 67(3):201-5. PubMed ID: 16611213
[TBL] [Abstract][Full Text] [Related]
3. Thermodynamic and computational studies on the binding of p53-derived peptides and peptidomimetic inhibitors to HDM2.
Grässlin A; Amoreira C; Baldridge KK; Robinson JA
Chembiochem; 2009 May; 10(8):1360-8. PubMed ID: 19408261
[TBL] [Abstract][Full Text] [Related]
4. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
Parks DJ; LaFrance LV; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Schubert C; Koblish HK; Zhao S; Franks CF; Lattanze J; Carver TE; Cummings MD; Maguire D; Grasberger BL; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jun; 16(12):3310-4. PubMed ID: 16600594
[TBL] [Abstract][Full Text] [Related]
5. N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.
Hayashi R; Wang D; Hara T; Iera JA; Durell SR; Appella DH
Bioorg Med Chem; 2009 Dec; 17(23):7884-93. PubMed ID: 19880322
[TBL] [Abstract][Full Text] [Related]
6. Miniature protein inhibitors of the p53-hDM2 interaction.
Kritzer JA; Zutshi R; Cheah M; Ran FA; Webman R; Wongjirad TM; Schepartz A
Chembiochem; 2006 Jan; 7(1):29-31. PubMed ID: 16397877
[No Abstract] [Full Text] [Related]
7. Helical beta-peptide inhibitors of the p53-hDM2 interaction.
Kritzer JA; Lear JD; Hodsdon ME; Schepartz A
J Am Chem Soc; 2004 Aug; 126(31):9468-9. PubMed ID: 15291512
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors of the p53-MDM2.
Hu CQ; Hu YZ
Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
[TBL] [Abstract][Full Text] [Related]
9. Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects.
Fry DC; Graves B; Vassilev LT
Methods Enzymol; 2005; 399():622-33. PubMed ID: 16338385
[TBL] [Abstract][Full Text] [Related]
10. Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
Pan W; Lahue BR; Ma Y; Nair LG; Shipps GW; Wang Y; Doll R; Bogen SL
Bioorg Med Chem Lett; 2014 Apr; 24(8):1983-6. PubMed ID: 24656661
[TBL] [Abstract][Full Text] [Related]
11. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction.
Fasan R; Dias RL; Moehle K; Zerbe O; Obrecht D; Mittl PR; Grütter MG; Robinson JA
Chembiochem; 2006 Mar; 7(3):515-26. PubMed ID: 16511824
[TBL] [Abstract][Full Text] [Related]
13. Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.
Azzarito V; Rowell P; Barnard A; Edwards TA; Macdonald A; Warriner SL; Wilson AJ
Chembiochem; 2016 Apr; 17(8):768-73. PubMed ID: 26690307
[TBL] [Abstract][Full Text] [Related]
14. Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp.
Tsukamoto S; Yoshida T; Hosono H; Ohta T; Yokosawa H
Bioorg Med Chem Lett; 2006 Jan; 16(1):69-71. PubMed ID: 16246554
[TBL] [Abstract][Full Text] [Related]
15. Designer macrocyclic organo-peptide hybrids inhibit the interaction between p53 and HDM2/X by accommodating a functional α-helix.
Smith JM; Frost JR; Fasan R
Chem Commun (Camb); 2014 May; 50(39):5027-30. PubMed ID: 24710524
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.
Tian Y; Ma Y; Gibeau CR; Lahue BR; Shipps GW; Strickland C; Bogen SL
Bioorg Med Chem Lett; 2016 Jun; 26(11):2735-8. PubMed ID: 27080185
[TBL] [Abstract][Full Text] [Related]
17. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
Surmiak E; Twarda-Clapa A; Zak KM; Musielak B; Tomala MD; Kubica K; Grudnik P; Madej M; Jablonski M; Potempa J; Kalinowska-Tluscik J; Dömling A; Dubin G; Holak TA
ACS Chem Biol; 2016 Dec; 11(12):3310-3318. PubMed ID: 27709883
[TBL] [Abstract][Full Text] [Related]
18. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity.
Leonard K; Marugan JJ; Raboisson P; Calvo R; Gushue JM; Koblish HK; Lattanze J; Zhao S; Cummings MD; Player MR; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jul; 16(13):3463-8. PubMed ID: 16647257
[TBL] [Abstract][Full Text] [Related]
19. Peptide-based inhibitors of protein-protein interactions.
Wójcik P; Berlicki Ł
Bioorg Med Chem Lett; 2016 Feb; 26(3):707-713. PubMed ID: 26764190
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.
Carry JC; Garcia-Echeverria C
Bioorg Med Chem Lett; 2013 May; 23(9):2480-5. PubMed ID: 23541651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]